Curanex Pharmaceuticals Inc
For the period ended Sep 30, 2025. Filed Nov 17, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 17, 2025
CURX$6.21+7.4%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Changes in Shareholders’ Equity
STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY
| Common Stock · Preferred Stock · Common Stock · Additional | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Shares · Amount · Number of Shares · Amount · to be issued · Paid in Capital · Accumulated Deficit · Total | ||||||||||
| Balance at December 31, 2023 | 600,000 | $60 | - | $ | - | $200,000 | $120,973 | $(260,943) | $60,090 | |
| Issuance of common stock | - | - | - | - | 150,000 | - | - | 150,000 | ||
| Net loss | - | - | - | - | - | - | (80,202) | (80,202) | ||
| Balance at March 31, 2024 | 600,000 | $60 | - | $ | - | $350,000 | $120,973 | $(341,145) | $129,888 | |
| Issuance of common stock | 23,400,000 | $2,340 | - | - | $(150,000) | $777,103 | - | $629,443 | ||
| Issuance of preferred stock | - | - | 1,000,000 | $100 | - | - | - | 100 | ||
| Net loss | - | - | - | - | - | - | (44,200) | (44,200) | ||
| Balance at June 30, 2024 | 24,000,000 | $2,400 | 1,000,000 | $100 | $200,000 | $898,076 | $(385,345) | $715,231 | ||
| Net loss | - | - | - | - | - | - | (91,166) | (91,166) | ||
| Balance at September 30, 2024 | 24,000,000 | $2,400 | 1,000,000 | $200 | $200,000 | $898,076 | $(476,511) | $624,165 | ||
| Balance at December 31, 2024 | 24,000,000 | $2,400 | 1,000,000 | $100 | $200,000 | $923,309 | $(622,449) | $503,360 | ||
| Net loss | - | - | - | - | - | - | (137,583) | (137,583) | ||
| Balance at March 31, 2025 | 24,000,000 | $2,400 | 1,000,000 | $100 | $200,000 | $923,309 | $(760,032) | $365,777 | ||
| Net loss | - | - | - | - | - | - | (60,346) | (60,346) | ||
| Balance at June 30, 2025 | 24,000,000 | $2,400 | 1,000,000 | $100 | $200,000 | $923,309 | $(820,378) | $305,431 | ||
| Issuance of common stock | 4,340,812 | $434 | - | - | $(200,000) | $15,140,396 | - | $14,940,831 | ||
| Net loss | - | - | - | - | - | - | (954,059) | (954,059) | ||
| Balance at September 30, 2025 | 28,340,812 | $2,834 | 1,000,000 | $100 | $ | - | $16,063,705 | $(1,774,437) | $14,292,202 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.